Kingchem (Liaoning) Life Science Co., Ltd.

SZSE:301509 Stok Raporu

Piyasa değeri: CN¥3.6b

Kingchem (Liaoning) Life Science Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Kingchem (Liaoning) Life Science has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.3% per year. Kingchem (Liaoning) Life Science's return on equity is 3.1%, and it has net margins of 11.7%.

Anahtar bilgiler

11.3%

Kazanç büyüme oranı

4.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi10.9%
Gelir büyüme oranı8.3%
Özkaynak getirisi3.1%
Net Marj11.7%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

A Look At The Fair Value Of Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509)

Sep 29
A Look At The Fair Value Of Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509)

We Think Kingchem (Liaoning) Life Science (SZSE:301509) Can Stay On Top Of Its Debt

Feb 27
We Think Kingchem (Liaoning) Life Science (SZSE:301509) Can Stay On Top Of Its Debt

Gelir ve Gider Dağılımı

Kingchem (Liaoning) Life Science nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SZSE:301509 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 245686711035
30 Jun 245979411733
31 Mar 2467715011729
31 Dec 2376717411830
30 Sep 2373615312629
30 Jun 2377417311528
31 Mar 2374315210628
01 Jan 2371716110526
30 Sep 2271417910723
30 Jun 2267014810425
31 Mar 226091169725
31 Dec 21549859025
31 Dec 20464597721
31 Dec 19415586917
31 Dec 18301275813

Kaliteli Kazançlar: 301509 has high quality earnings.

Büyüyen Kar Marjı: 301509's current net profit margins (11.7%) are lower than last year (20.7%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 301509's earnings have grown by 11.3% per year over the past 5 years.

Büyüme Hızlandırma: 301509's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Kazançlar vs. Sektör: 301509 had negative earnings growth (-56.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


Özkaynak Getirisi

Yüksek ROE: 301509's Return on Equity (3.1%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin